A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792).
Participation in the study will last about 18 months.
Inclusion Criteria:
Exclusion Criteria:
Sun City West, Arizona 85375, United States
CABA, 1204, Argentina
Luoyang Shi, 471003, China
Shinjuku-ku, 160-0008, Japan
Suita-shi, 565-0853, Japan
Yamato-shi, 242-0004, Japan